Bactiguard Holding AB (publ) (BACTI_B) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the BactiGuard Q3 2025 report presentation. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to the speakers, CEO Christine Lind and CFO Patrick Bock. Please go ahead. Thank you, operator. and welcome to the presentation of Back to Guard's report for the third quarter of 2025. Our CFO, Patrick Buck, and I will go through the presentation together, and we will have a Q&A session towards the end. Let's start with some high-level comments on the quarter, and Patrick will go into more financial details later in the presentation. We have had another profitable quarter with EBITDA totaling 5.3 million SEC, And the investments we have made over the last two years in strengthening the organization and capabilities to support licensing have not jeopardized our margins or impacted profitability. Even though we do not yet demonstrate significant top-line growth, we deliver a strong EBITDA, and I am confident that we are equipped to execute on the opportunities for our infection prevention technology across our strategic therapeutic areas. Total revenues were just over 48 million SEC with license revenues of almost 30 million SEC. Given our substantial US dollar exposure, which in the license business, the weaker US dollar does continue to impact these revenues negatively. We also had an exceptionally strong third quarter in 2024, which set a high base for comparison. Revenues from the BD partnership bounced back in Q3 compared with Q2 and totaled 28.3 million SEC. Notably, this quarter is the third strongest quarter of the last 10 quarters from the partnership, wi...